Virtual Library
Start Your Search
C. Taka
Author of
-
+
P2.10 - Poster Session 2 - Chemotherapy (ID 207)
- Event: WCLC 2013
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 1
- Moderators:
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.10-027 - Mutation of epidermal growth factor receptor gene and efficacy of gefitinib in squamous cell carcinoma of lung (ID 1582)
09:30 - 09:30 | Author(s): C. Taka
- Abstract
Background
The epidermal growth factor receptor (EGFR) gene mutation has been reported as an important predictive factor for EGFR-tyrosine kinase inhibitor (TKI) efficacy in NSCLC. In "The Lung Cancer Diagnosis and Treatment Guideline published by The Japan Lung Cancer Society 2012 edition", the EGFR gene mutation is strongly recommended to be analyzed in deciding the treatment policy of advanced non- squamous cell carcinoma. In addition, it is known that the EGFR gene mutation is frequently observed in adenocarcinoma (Ad), but very rare in squamous cell carcinoma (Sq). Efficacy of EGFR-TKI in EGFR gene mutation positive Sq has not examined enough.Methods
We obtained tumor samples from 50 patients diagnosed as Sq (excluded Ad-Sq carcinoma) by two or more pathologist between January 2008 to March 2013. The EGFR gene mutation status was determined by PCR-Invader assay (BML Incorporation) and direct sequencing method.Results
EGFR gene mutations were detected in 2 of 50 (4%) samples. Common characteristics of two patients were male, elderly, high level of CEA, and good PS. One patient was an on-smoker and the other was a heavy smoker. The type of the EGFR gene mutation was both exon 21 point mutation. Gefitinib was administered to two patients and PRs were observed. Their progression-free-suvival were 9 months and 20 months.Conclusion
The frequency of the EGFR gene mutation in Sq was low. However, it was suggested that gene mutation positive Sq is responded to EGFR-TKI. It is necessary to analyze the EGFR gene mutation in Sq.
